vutrisiran (Amvuttra)

Indications

• treatment of polyneuropathy of hereditary transthyretin amyloidosis in adults

Dosage

• 25 mg SQ every 3 months

0.5 mL vutrisiran 50 mm/mL Prefilled Syringe

Adverse effects

• reduced vitamin A*
• arthralgia
• dyspnea

* supplement with the recommended daily allowance of vitamin A

Mechanism of action

• transthyretin-directed small interfering RNA

More general terms

• neurologic agent
• short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)